Amicus Therapeutics Announces Presentations and Posters at Lysosomal Disease Network WORLD Symposium

CRANBURY, N.J., Jan. 30, 2014 (GLOBE NEWSWIRE) -- Amicus Therapeutics FOLD today announced that three oral presentations and five posters highlighting its development programs for lysosomal storage diseases will be included at the 10^th Annual Lysosomal Disease Network WORLD Symposium (LDN WORLD), to be held February 10-14, 2014 in San Diego, CA.

Oral Platform Presentations:

Pompe Disease:

• Chemical Conjugation of Targeting Peptide to ERTs Improve Receptor Binding and Substrate Clearance in Mouse Models of Disease – Hung Do, PhD, Amicus Therapeutics, Inc. (Wednesday, February 12 at 2:45 p.m. PT)

Fabry Disease:

• Phase 3 Study (FACETS) of Migalastat HCl for Fabry Disease: Post hoc GLA Mutation-Based Identification of Subjects Likely to Show a Drug Effect – Jeffrey P. Castelli, PhD, Amicus Therapeutics, Inc. (Thursday, February 13 at 11:15 a.m. PT)

Gaucher Disease:

• Glucosylceramide and Glucosylsphingosine Quantitation by Liquid Chromatography-Tandem Mass Spectrometry to Enable Studies of Neuronopathic Gaucher Disease – Rick Hamler, Amicus Therapeutics, Inc. (Tuesday, February 11 at 10:30 a.m. PT)

Posters: Tuesday, February 11 - Thursday, February 13, 4:00-6:00 p.m. PT

Pompe Disease:

• Chemical Conjugation of Targeting Peptide to ERTs Improve Receptor Binding and Substrate Clearance in Mouse Models of Disease – Russell Gotschall, Amicus Therapeutics, Inc.
   
• Subcutaneous Administration of Recombinant Human Acid Alpha-Glucosidase Co-formulated with the Pharmacological Chaperone AT2220 Leads to Lysosomal Uptake of rhGAA and Glycogen Reduction in Disease-relevant Tissues of Pompe Mice – Yi Lun, Amicus Therapeutics, Inc.
   
• Strategy to Assess the Effect of Duvoglustat Co-administered with Alglucosidase Alfa Infusion on the Immune Response to Enzyme Replacement Therapy for Pompe Disease – Xiaoyang Wu, Amicus Therapeutics, Inc.
   
• Liquid Chromatography-Tandem Mass Spectrometry Determination of AT2220 in Rodent Plasma and Tissues – Leo B. Dungan, Amicus Therapeutics, Inc.

Fabry Disease:

• Phase 3 Study (FACETS) of Migalastat HCl for Fabry Disease: Post hoc GLA Mutation-Based Identification of Subjects Likely to Show a Drug Effect – Elfrida R. Benjamin, Amicus Therapeutics, Inc.

About Amicus Therapeutics

Amicus Therapeutics FOLD is a biopharmaceutical company at the forefront of therapies for rare and orphan diseases. The Company is developing novel, first-in-class treatments for a broad range of human genetic diseases, with a focus on delivering new benefits to individuals with lysosomal storage diseases. Amicus' lead programs include the small molecule pharmacological chaperones migalastat HCl as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat HCl) in combination with ERT for Pompe disease.